Even As Senate Is Poised To Pass Opioid Package, Many Controversial Issues Involving The Crisis Left Untouched

More contentious policies -- like protecting patient privacy and Medicaid funding -- are likely to be kicked down the road until the lame-duck session following the midterm elections. Meanwhile, the FDA wants to encourage the drug industry to develop nonaddictive alternatives to opioids, and the company that makes Narcan eyes schools as an untapped market.

from Kaiser Health News https://ift.tt/2okOfH0